The mission of our conference is to understand the issues surrounding early diagnosis of lung cancer, how to optimize early treatment, and to expand practice-relevant research to medical and scientific communities in the U.S. and abroad. The Early Lung Cancer Action Program (ELCAP) screening effort began in 1992 and evolved into the International Early Lung Cancer Action Program (I-ELCAP). By providing training and the ELCAP Management System to those interested in screening, such programs expanded worldwide. The resulting data and analyses from these sites provide new diagnostic knowledge that is integrated into the continually updated screening regimen so that it remains state-of-the-art; and screening advances are addressed at every conference. In addition, The Early Lung Cancer Research on Treatment (IELCART) study uses the power of the prospective cohort design to accumulate data on clinical care treatment, similar in design to the I-ELCAP cohort. That data analysis is used to address questions efficiently about stage I lung cancer treatments. The IELCART research goal is to maximize the benefit of screening by determining optimal treatments when disease is discovered. And finally, the newest focus of research at this conference is on interstitial lung disease (ILD). Following the same research paradigms as I-ELCAP & IELCART we have developed an ILD registry and are recruiting collaborating sites.

**Friday, March 16th**

**8:30**
Registration. Coffee and Danish (provided)

**9:00 – 10:00**
Conference welcome. J. P. Smith, I-ELCAP Advisory Board
Program overview and updates. Moderator: J.P. Smith
I-ELCAP and IELCART. C. Henschke

**10:00 – 11:30**
The benefit of full implementation of screening. Moderator: J. Mulshine
10:00 – 10:15 The NLST results: estimating the extent of the benefit. D. Yankelevitz
10:15 – 10:30 Modeling the benefit of continued screening. O. Gorlova
10:30 – 10:45 Impact of discontinuing continuous screening. H. Schmidt
10:45 – 11:00 Benefit of screening in the NCCN Group II. A McKee
11:00 – 11:15 Constructing a shared decision-making document. F. Grannis
11:15 – 11:30 Discussion.

**11:30 – 11:45**
Coffee Break and Group Picture

**11:45 – 12:30**
Stage I lung cancer. Moderator: R. Flores
11:45 – 12:00 Treatment alternatives for second primaries. D. Lee
12:00 – 12:15 Changes in lung volume after treatment. M. Chung
12:15 – 12:30 Differences in surgical decision-making. R. Yip

**12:30 – 1:45**
Lunch (provided)

**1:45 – 2:45**
Preliminary findings from IELCART. Moderator: E. Taioli
1:45 – 2:00 Distribution of stage I lung cancer. C. Henschke
2:00 – 2:15 Surgical margins. A. Wolf
2:15 – 2:30 Surgical complications and length of stay. D. Nicastri
2:30 – 2:45 Quality of life measures and implications. R. Schwartz

**2:45 – 3:45**
Radiation therapy vs. surgery. Moderator: K. Rosenzweig
2:45 – 3:00 Meta-analysis of surgery vs. radiation therapy E. Taioli
3:00 – 3:15 Is a comparison justified at this time? R. Flores
3:15 – 3:30 Will the current VALOR trial succeed? D. Moghanaki
3:30 – 3:45 Can we confidently answer the question without RCTs? J. Wisnivesky

**3:45 – 4:00**
Coffee Break
Friday, March 16th (continued)

4:00 – 5:30  How to involve the general medical practitioner. Moderator: J. Wisnivesky
  4:00 – 4:15  Screening—why not? R. Flores
  4:15 - 4:30  Attitudes about lung cancer screening: primary care perspective. J. Lin
  4:30 – 4:45  Attitudes about lung cancer screening: pulmonologist perspective. L. Di Fabrizio
  4:45 – 5:00  The role of personalized shared decision making. M. Kale
  5:00 – 5:15  Change the face of lung cancer screening. C. Draft
  5:15 – 5:30  Discussion.

5:30 – 6:30  Closed meeting for I-ELCAP and IELCART members

Saturday, March 17th

8:30  Registration. Coffee and Danish (provided)

9:00 – 9:45  COPD and lung cancer screening. Moderator: J. Zulueta
  9:00 – 9:15  Implication of undocumented COPD. D. Steiger
  9:15 – 9:30  Types of COPD and lung cancer survival. J. Gonzalez
  9:30 – 9:45  Implications for screening. J. Zulueta

9:45 – 10:30  Liver-lung interactions. Moderator: A. Branch
  9:45 – 10:00  Effect of hypoxia and sleep apnea on the liver. A. Branch
  10:00 – 10:15  Impact of cigarette smoke and other air-born toxins on liver function risk. A. Asgharpour
  10:15 – 10:30  Diseases of the lung-liver axis. P. Perumalswami

10:30 – 11:00  Coffee Break

11:00 – 12:00  Interstitial lung disease. Moderator: M. Padilla
  11:00 – 11:15  In vivo optical imaging for diagnosis. L. Hariri
  11:15 – 11:30  Advances in surgical techniques for ILD. A. Kaufman
  11:30 – 11:45  Early diagnosis of ILD. M. Salvatore
  11:45 – 12:00  Role of screening: common mechanisms. G. Raghu

12:00 – 12:45  Cost-effectiveness. Moderator: B. Pyenson
  12:00 – 12:15  Summary of models for CT screening for lung cancer. R. Yip
  12:15 – 12:30  Applications of agent-based modeling. Y. Li
  12:30 – 12:45  Overall consistency of cost-effectiveness results. B. Pyenson

12:45 – 1:30  Lunch (provided)

1:30 – 2:15  VA screening initiatives. Moderator: D. Moghanaki
  1:30 – 1:45  Insights from the VA perspective. R. Sherrier
  1:45 – 2:00  Phoenix outreach and screening program. S. Aguayo
  2:00 – 2:15  MVP and lung cancer screening. B. Johnson/L. Selva

2:15 – 3:00  The promise of large databases, radiomics and deep learning.
  Moderator: M. Giger
  2:15 – 2:30  Overview on radiomics and deep learning. M. Giger
  2:30 – 2:45  Lung CT and deep learning. J. Lee
  2:45 – 3:00  Future infrastructure for processing big data. G. Tourassi

3:00 – 3:15  Coffee Break

  3:15 – 3:30  Why does it matter and how do we monitor it? R. Subramaniam
  3:30 – 3:45  The role of Quantitative Imaging Biomarker Alliance (QIBA). E. Jackson
  3:45 – 4:00  Automated Image Quality Assessment for Chest CT. A.Reeves
  4:00 – 4:15  Results from crowd sourcing. R. Avila